A Phase 2 Study of F-652, a Novel Tissue-Targeted Recombinant Human Interleukin-22 (IL-22) Dimer, for Treatment of Newly Diagnosed Acute Gvhd of the Lower GI Tract-MedSci.cn

A Phase 2 Study of F-652, a Novel Tissue-Targeted Recombinant Human Interleukin-22 (IL-22) Dimer, for Treatment of Newly Diagnosed Acute Gvhd of the Lower GI Tract

Ponce, DM; Alousi, AM; Nakamura, R; Sandhu, KS; Barker, JN; Shia, J; Yan, XQ; Daley, WL; Moore, G; Fatmi, S; Soto, C; Gomes, A; Slingerland, J; Giardina, P; Peled, JU; van den Brink, MRM; Hanash, AM

BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2020; 26 (3): S51

科室
- - 订阅+
  - 更多科室
工具
服务